- Home
- IPW vs NRXS Comparison
IPW vs NRXS Comparison
Compare IPW & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPW
- NRXS
- Stock Information
- Founded
- IPW 2018
- NRXS 2011
- Country
- IPW United States
- NRXS United States
- Employees
- IPW N/A
- NRXS N/A
- Industry
- IPW Catalog/Specialty Distribution
- NRXS
- Sector
- IPW Consumer Discretionary
- NRXS
- Exchange
- IPW Nasdaq
- NRXS Nasdaq
- Market Cap
- IPW 15.7M
- NRXS 13.0M
- IPO Year
- IPW 2021
- NRXS 2023
- Fundamental
- Price
- IPW $0.66
- NRXS $2.61
- Analyst Decision
- IPW Strong Buy
- NRXS
- Analyst Count
- IPW 1
- NRXS 0
- Target Price
- IPW $2.75
- NRXS N/A
- AVG Volume (30 Days)
- IPW 531.4K
- NRXS 4.9M
- Earning Date
- IPW 05-15-2025
- NRXS 05-12-2025
- Dividend Yield
- IPW N/A
- NRXS N/A
- EPS Growth
- IPW N/A
- NRXS N/A
- EPS
- IPW N/A
- NRXS N/A
- Revenue
- IPW $74,105,251.00
- NRXS $2,934,945.00
- Revenue This Year
- IPW $8.31
- NRXS $138,883.78
- Revenue Next Year
- IPW $77.15
- NRXS $118.59
- P/E Ratio
- IPW N/A
- NRXS N/A
- Revenue Growth
- IPW N/A
- NRXS 27.52
- 52 Week Low
- IPW $0.41
- NRXS $1.33
- 52 Week High
- IPW $3.65
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- IPW 67.58
- NRXS 50.48
- Support Level
- IPW $0.43
- NRXS $2.57
- Resistance Level
- IPW $0.94
- NRXS $2.82
- Average True Range (ATR)
- IPW 0.10
- NRXS 0.44
- MACD
- IPW 0.01
- NRXS -0.05
- Stochastic Oscillator
- IPW 44.29
- NRXS 10.25
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).